(Q34571555)

3 August 2017

1 reference

title

Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs (English)

1 reference

3 August 2017

1 reference

Robin L Jones

1

1 reference

PubMed ID

17020459

3 August 2017

Michael S Ewer

series ordinal

2

1 reference

3 August 2017

1 September 2006

1 reference

Expert Review of Anticancer Therapy

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

1249-1269

1 reference

3 August 2017

9

1 reference

Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiotoxicity of interferon. A review of 44 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Effects of probucol on endothelial damage by 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

5-Fluorouracil induces arterial vasocontractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Coronary spasm induced by capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Capecitabine-induced severe hypertriglyceridemia: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiac pathologic findings in patients treated with bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Acute stroke following cisplatin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Left ventricular and cardiac autonomic function in survivors of testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Endocrinological late effects after chemotherapy for testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Long-term sequelae of treatment for testicular germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Myocardial ischemia associated with high-dose carmustine infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

The cytosine arabinoside (Ara-C) syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Acute left ventricular failure following melphalan and fludarabine conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Vincristine-induced myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Letter: Myocardial infarction: a complication of vincristine treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Reversible myocardial ischaemia following vincristine containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Myocardial infarction associated with vinorelbine (Navelbine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Stress pathways and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Phase I trial of combretastatin a-4 phosphate with carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Reversible cardiac arrhythmia in a breast cancer patient treated with recombinant alpha interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Mechanisms of arsenic-induced prolongation of cardiac repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Myocardial ischemia in a patient with acute lymphoblastic leukemia during L-asparaginase therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Toxicity of E. coli L-asparaginase in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Effects of thalidomide on QTc, inotropy, and lusitropy in the isolated guinea pig heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Treatment of Advanced Lymphomas with Bleomycin (NSC-125066)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

Acute Coronary Events Following Cisplatin-Based Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1249

10.1586/14737140.6.9.1249

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

17020459